Minapharm Pharmaceuticals reports 3.7% YoY higher consolidated profit in H1

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products

Staff Writer, Arab Finance

September 1, 2022

PHOTO

Minapharm Pharmaceuticals (Minapharm) (MIPH) posted a 3.7% year-on-year (YoY) growth in consolidated profit excluding minority interest and income taxes during the first half (H1) of 2022, according to financial statements filed to the Egyptian Exchange (EGX) on Wednesday.

The company’s consolidated profits attributable to the parent company reached EGP 264.81 million in H1 2022, up from EGP 255.358 million in H1 2021.

Revenue surged to EGP 1.66 billion in the six-month period ended June from EGP 1.454 billion the year before.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It distributes its products within and outside Egypt.

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.